Next Article in Journal
Hitting the Bull’s-Eye in Metastatic Cancers—NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death
Next Article in Special Issue
Wharton’s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease
Previous Article in Journal
Acknowledgement to Reviewers of Pharmaceuticals in 2014
Previous Article in Special Issue
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2015, 8(1), 40-61;

γδ T Cell Immunotherapy—A Review

Transfusion Medicine and Cell Processing, Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
Center for Therapeutic Innovation, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
Authors to whom correspondence should be addressed.
Academic Editor: Shin Mineishi
Received: 6 January 2015 / Accepted: 2 February 2015 / Published: 12 February 2015
(This article belongs to the Special Issue Cell Therapy)
Full-Text   |   PDF [778 KB, uploaded 12 February 2015]   |  


Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy. View Full-Text
Keywords: cancer immunotherapy; nitrogen-containing bisphosphonate; phosphoantigen; tumor; Vγ9Vδ2 T cell cancer immunotherapy; nitrogen-containing bisphosphonate; phosphoantigen; tumor; Vγ9Vδ2 T cell

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kobayashi, H.; Tanaka, Y. γδ T Cell Immunotherapy—A Review. Pharmaceuticals 2015, 8, 40-61.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top